You are here

  • Home
  • Archive
  • Volume 10, Issue 12
  • SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response

Article info

Article menu
Immunotherapy biomarkers
Original research
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response

Authors

  • Kranthi Kiran Kishore Tanagala Section of Oral, Diagnostic and Rehabilitation Sciences, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York City, New York, USACancer Biology and Immunology Laboratory, College of Dental Medicine, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Joshua Morin-Baxter Section of Oral, Diagnostic and Rehabilitation Sciences, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York City, New York, USACancer Biology and Immunology Laboratory, College of Dental Medicine, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Richard Carvajal Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Maryum Cheema Section of Oral, Diagnostic and Rehabilitation Sciences, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York City, New York, USACancer Biology and Immunology Laboratory, College of Dental Medicine, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Sunil Dubey Section of Oral, Diagnostic and Rehabilitation Sciences, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York City, New York, USACancer Biology and Immunology Laboratory, College of Dental Medicine, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Hiroshi Nakagawa Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, NY, USA PubMed articlesGoogle scholar articles
  • Angela Yoon Department of Stomatology, Division of Diagnostic science and Services, College of Dental Medicine, Medical University of South Carolina, Charleston, South Carolina, USA PubMed articlesGoogle scholar articles
  • Yi-Shing L Cheng Department of Diagnostic Sciences, Texas A&M University System, Dallas, Texas, USA PubMed articlesGoogle scholar articles
  • Alison Taylor Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032 PubMed articlesGoogle scholar articles
  • Jeffrey Nickerson Division of Genes & Development, Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Akiva Mintz Section of Oral, Diagnostic and Rehabilitation Sciences, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York City, New York, USADepartment of Radiology, Columbia University Medical Center, New York, NY, 10032 PubMed articlesGoogle scholar articles
  • Fatemeh Momen-Heravi Section of Oral, Diagnostic and Rehabilitation Sciences, Columbia University College of Dental Medicine, Columbia University Irving Medical Center, New York City, New York, USACancer Biology and Immunology Laboratory, College of Dental Medicine, Columbia University Irving Medical Center, New York, New York, USAHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA PubMed articlesGoogle scholar articles

Citation

Tanagala KKK, Morin-Baxter J, Carvajal R, et al
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
Journal for ImmunoTherapy of Cancer 2022;10:e005088. doi: 10.1136/jitc-2022-005088
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.